ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/alkylating-agent
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/alkylating-agent
67
trial(s) found.
NCT07764978
Haem
Phase 3
Recruiting
Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (
DURGA-5
)
autologous CAR-T-cell therapy,BCMA/CD19-targeting
+ alkylating agent
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07735637
Haem
Phase 3
Not yet recruiting
A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment With AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, Versus Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (TE NDMM) (
DURGA-6
)
autologous CAR-T-cell therapy,BCMA/CD19-targeting
+ alkylating agent
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07651618
Advanced
Phase 2
Not yet recruiting
PERTIL-01
: A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma
Aldesleukin
Cyclophosphamide
Fludarabine
IL-2 variant
alkylating agent
antimetabolite
cancer therapy
cancer therapy,IL-2-targeting
cytokine therapy
cytokine therapy,IL-2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,IL-2-targeting
+ alkylating agent
Melanoma
Skin cancer
WA
6000 - Perth - Royal Perth Hospital
NCT07489495
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants With Advanced RCC Who Have Progressed on or After Both PD-1/L1 and VEGF-TKI Therapies in Sequence or in Combination (LITESPARK-034) (
6482-034
)
HIF2a inhibitor
MET/VEGFR2/AXL/MER inhibitor
placebo
+ alkylating agent
Clear cell renal cell carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT07479797
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy (
KT-US-740-0603
)
autologous CAR-T-cell therapy,CD19-targeting
autologous CAR-T-cell therapy,CD19/CD20-targeting
+ alkylating agent
Diffuse large B-cell lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
NCT07405164
Advanced
Phase 3
Recruiting
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long-term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043) (
6482-043
)
HIF2a inhibitor
+ alkylating agent
Cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT07334301
Paed
Phase 1 / Phase 2
Recruiting
A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma (
BEACON2
)
Bevacizumab
Dinutuximab
Irinotecan
Temozolomide
Topotecan
alkylating agent
anti-GD2 monoclonal antibody
anti-VEGF monoclonal antibody
cancer therapy
cancer therapy,GD2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
immuno-oncology therapy,GD2-targeting
immuno-oncology therapy,VEGF-targeting
topoisomerase inhibitor
+ alkylating agent
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT07227402
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (
LITESPARK-033
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
HIF2a inhibitor
KIT inhibitor
MET/VEGFR2/AXL/MER inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
+ alkylating agent
Clear cell renal cell carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
NCT07224672
Haem
Phase 2
Recruiting
A Phase 2, Open-label, Randomized, Dose Optimization Study Evaluating the Efficacy and Safety of Belantamab Mafodotin Administered in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain Amyloidosis (
ALANIS
)
alkylating agent
anti-BCMA-immunoconjugate
glucocorticoid
proteasome inhibitor
AL amyloidosis
NSW
2145 - Westmead - The Children's Hospital at Westmead
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT07149857
Haem
Phase 2
Recruiting
A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel (
CARTITUDE-10
)
autologous CAR-T-cell therapy,BCMA-targeting
+ alkylating agent
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07100730
Radonc
Phase 3
Recruiting
A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients With Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX BrIGHT [IPAX-3]) (
IPAX-BrIGHT
)
alkylating agent
radioiodine conjugate
Glioblastoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06966700
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (
2870-032
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
platinum-based antineoplastic agent
taxane
+ alkylating agent
Breast cancer
HER2-negative breast cancer
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6035 - Wellington - Bowen Hospital
NCT06846671
Haem
Phase 3
Recruiting
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors (
CaDAnCe-302
)
BTK PROTAC degrader
Bcl2 inhibitor
PI3K delta inhibitor
alkylating agent
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2139 - Concord - Concord Repatriation General Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4350 - Toowoomba - Toowoomba Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6005 - West Perth - Perth Blood Institute
NCT06816927
Advanced
Phase 2
Recruiting
A Multi-Center, Randomized, Phase 2 Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (
GIANT
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
+ alkylating agent
Glioblastoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06801834
Advanced
Phase 3
Recruiting
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC) (
EVOKE-SCLC-04
)
anti-Trop2 antibody-drug conjugate
+ alkylating agent
Small-cell lung cancer
NSW
2500 - Wollongong - Cancer Care Wollongong
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06717347
Haem
Phase 3
Recruiting
A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010) (
2140-010
)
anti-ROR1 antibody-drug conjugate
+ alkylating agent
Diffuse large B-cell lymphoma
VIC
3066 - Epping - Northern Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4812 - Townsville - Townsville University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT06615479
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (
CA088-1007
)
autologous CAR-T cell therapy,GPRC5D-targeting
immunomodulatory imide drug
+ alkylating agent
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06564038
Haem
Phase 1 / Phase 2
Recruiting
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies (
Soundtrack-E
)
bispecific T-cell engager,CD19-targeting
+ alkylating agent
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Mantle cell lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06500273
Haem
Phase 2
Recruiting
A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma (
ALPHA3
)
allogeneic CAR-T-cell therapy,CD19-targeting
+ alkylating agent
Diffuse large B-cell lymphoma
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
WA
6009 - Nedlands - Hollywood Private Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06486051
Haem
Phase 2
Recruiting
A Phase 2 Trial to Evaluate the Efficacy and Safety of WZTL-002 in Patients With Relapsed or Refractory Large B-cell Lymphoma (
ENABLE-2
)
autologous CAR-T-cell therapy,CD19-targeting
+ alkylating agent
Diffuse large B-cell lymphoma
Non-Hodgkin's lymphoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06401330
Paed
Phase 3
Recruiting
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) (
AREN2231
)
Carboplatin
Cyclophosphamide
Dactinomycin
Doxorubicin
Etoposide
Irinotecan
Vincristine
alkylating agent
anthracycline
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
+ alkylating agent
Wilms tumour
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT06333899
Paed
Phase 1
Recruiting
A Pilot Study of Lorlatinib for Treatment of Children With Newly Diagnosed High-Grade Glioma With ROS-1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase) or ALK (Anaplastic Lymphoma Kinase) Fusion (
CONNECT-TarGeT-L
)
ALK inhibitor,third generation
ROS1 inhibitor
+ alkylating agent
Anaplastic astrocytoma
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Glioblastoma
Glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT06208657
Paed
Phase 1 / Phase 2
Recruiting
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer (
OPTIMISE
)
Irinotecan
Nivolumab
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Relatlimab
Temozolomide
alkylating agent
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
cancer therapy
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
topoisomerase inhibitor
+ alkylating agent
Cancer
Central nervous system cancer
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06203210
Advanced
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (
IDeate-Lung02
)
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
+ alkylating agent
Small-cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06161974
Paed
Phase 2
Recruiting
Phase 2 Study of Olutasidenib With Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations (
TarGeT-D
)
IDH1 R132 inhibitor
alkylating agent
Astrocytoma
Cancer
Central nervous system cancer
Diffuse intrinsic pontine glioma
Glioma
H3K27M-mutant glioma
High-grade glioma
Oligodendroglioma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT06124157
Paed
Phase 2
Recruiting
An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia (
NCI-2023-09214
)
bispecific T-cell engager,CD19-targeting
+ alkylating agent
Acute lymphoblastic leukaemia
NSW
2305 - New Lambton Heights - John Hunter Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT06091865
Haem
Phase 3
Recruiting
A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 \xD7 Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (
OLYMPIA-3
)
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
+ alkylating agent
Diffuse large B-cell lymphoma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4217 - Benowa - Pindara Private Hospital
NCT05999994
Paed
Phase 2
Recruiting
CAMPFIRE
: Children's and Young Adult Master Protocol for Innovative Pediatric Research
Abemaciclib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Cyclophosphamide
Docetaxel
Gemcitabine
Irinotecan
Ramucirumab
Temozolomide
Vinorelbine
alkylating agent
anti-VEGFR2 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,VEGFR2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,VEGFR2-targeting
taxane
topoisomerase inhibitor
vinca alkaloid
+ alkylating agent
Cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT05991388
Paed
Phase 2 / Phase 3
Recruiting
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (
Glo-BNHL
)
Carboplatin
Dexamethasone
Etoposide
Ifosfamide
Loncastuximab Tesirine
Odronextamab
Rituximab
alkylating agent
anti-CD19 antibody-drug conjugate
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
cancer therapy
cancer therapy,CD19-targeting
cancer therapy,CD20-targeting
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD19-targeting
immuno-oncology therapy,CD20-targeting
platinum-based antineoplastic agent
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
topoisomerase inhibitor
+ alkylating agent
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05843253
Paed
Phase 2
Recruiting
Phase 2 Study of Ribociclib-Containing Post-Radiotherapy Combinations in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma: Ribociclib and Everolimus for HGG/DIPG Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways AND Ribociclib and Temozolomide for DHG, H3G34-mutant (
CONNECT-TarGeT-A
)
CDK4/6 inhibitor
alkylating agent
mTORC1 inhibitor
radiotherapy
Anaplastic astrocytoma
Central nervous system cancer
Diffuse hemispheric glioma
Diffuse intrinsic pontine glioma
Glioblastoma
Glioma
H3K27M-mutant glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05826535
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of Rondecabtagene Autoleucel, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants With Aggressive B-Cell Non-Hodgkin Lymphoma (
LYL314-101
)
autologous CAR-T-cell therapy,CD19/CD20-targeting
+ alkylating agent
Diffuse large B-cell lymphoma
Non-Hodgkin's lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05533775
Paed
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (
iMATRIX-GLO
)
bispecific T-cell engager,CD20-targeting
+ alkylating agent
Non-Hodgkin's lymphoma
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05504291
Paed
Phase 2
Recruiting
Intravitreal Melphalan for Intraocular Retinoblastoma (
ARET2121
)
alkylating agent
Retinoblastoma
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
WA
6009 - Perth - Perth Children's Hospital
NCT05417594
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (
CERTIS1
)
PARP1-selective inhibitor
+ alkylating agent
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05304585
Paed
Phase 3
Recruiting
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma (
ARST2032
)
Cyclophosphamide
Dactinomycin
Radiotherapy
Vincristine
alkylating agent
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
vinca alkaloid
+ alkylating agent
Alveolar rhabdomyosarcoma
Embryonal rhabdomyosarcoma
Sclerosing rhabdomyosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05139017
Haem
Phase 2 / Phase 3
Recruiting
A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003) (
2140-003
)
anti-ROR1 antibody-drug conjugate
+ alkylating agent
Diffuse large B-cell lymphoma
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4812 - Townsville - Townsville University Hospital
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04989803
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma (
PALISADES-1
)
autologous CAR-T-cell therapy,CD19/CD20-targeting
+ alkylating agent
B-cell lymphoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT04684368
Radonc
Phase 2
Recruiting
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (
ACNS2021
)
Carboplatin
Etoposide
Filgrastim
Ifosfamide
Mesna
Pegfilgrastim
Radiotherapy
Thiotepa
alkylating agent
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
sodium mercaptoethanesulfonate
topoisomerase inhibitor
+ alkylating agent
Choriocarcinoma
Germ cell tumour
Germinoma
Mixed germ cell tumour
Teratoma
Testicular embryonal carcinoma
Yolk sac tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04625907
Radonc
Phase 1 / Phase 2
Recruiting
FaR-RMS
: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Cyclophosphamide
Dactinomycin
Doxorubicin
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
Ifosfamide
Irinotecan
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
PDGFR inhibitor
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
VEGFR inhibitor
Vincristine
Vinorelbine
alkylating agent
anthracycline
antineoplastic antibiotic
cancer therapy
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cytotoxic chemotherapy
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
topoisomerase inhibitor
vinca alkaloid
+ alkylating agent
Rhabdomyosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Children's Hospital at Westmead
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04332822
Haem
Phase 3
Recruiting
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (
POLAR-BEAR
)
anti-CD79b antibody-drug conjugate
+ alkylating agent
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT04322318
Advanced
Phase 2
Recruiting
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) (
AREN1921
)
Carboplatin
Cyclophosphamide
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Radiotherapy
Topotecan
Vincristine
alkylating agent
anthracycline
cancer therapy
cytotoxic chemotherapy
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
+ alkylating agent
Wilms tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04221035
Radonc
Phase 3
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (
HR-NBL2
)
Busulfan
Carboplatin
Cisplatin
Cyclophosphamide
Dacarbazine
Dinutuximab
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Melphalan
Radiotherapy
Temozolomide
Thiotepa
Vincristine
alkylating agent
anthracycline
anti-GD2 monoclonal antibody
cancer therapy
cancer therapy,GD2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,GD2-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
+ alkylating agent
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT04031677
Curative
Phase 3
Recruiting
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS) (
STRASS2
)
Dacarbazine
Doxorubicin
Epirubicin
Ifosfamide
alkylating agent
anthracycline
cancer therapy
cytotoxic chemotherapy
+ alkylating agent
Leiomyosarcoma
Liposarcoma
Peritoneal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT03970447
Radonc
Phase 2 / Phase 3
Recruiting
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (
GBM-AGILE
)
ATM inhibitor
AZD1390
Dianhydrogalactitol
FGFR1/2/3 inhibitor
FGFR1 inhibitor
FGFR2 inhibitor
FGFR3 inhibitor
FGFR4 inhibitor
FGFR inhibitor
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KIT inhibitor
KIT inhibitor,first generation
Lomustine
PDGFR inhibitor
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Pegargiminase
RET inhibitor
Radiotherapy
Regorafenib
Temozolomide
Troriluzole
VEGFR inhibitor
alkylating agent
arginine deiminase-polyethylene glycol conjugate
cancer therapy
cancer therapy,ATM-targeting
cancer therapy,FGFR-targeting
cancer therapy,FGFR1-targeting
cancer therapy,FGFR1/2/3-targeting
cancer therapy,FGFR2-targeting
cancer therapy,FGFR3-targeting
cancer therapy,FGFR4-targeting
cancer therapy,KIT-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,RET-targeting
cancer therapy,VEGFR-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
glutamate modulator
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
pan-FGFR inhibitor
pan-FGFR inhibitor,reversible
+ alkylating agent
Glioblastoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
NCT03959085
Haem
Phase 3
Recruiting
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (
AALL1732
)
anti-CD22 antibody-drug conjugate
+ alkylating agent
Acute lymphoblastic leukaemia
B-cell acute lymphoblastic leukaemia/lymphoma
Leukaemia
Mixed phenotype acute leukaemia
NSW
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Perth - Perth Children's Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT03666000
Haem
Phase 1
Recruiting
A Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (
PBCAR0191-01
)
allogeneic CAR-T-cell therapy,CD19-targeting
+ alkylating agent
B-cell acute lymphoblastic leukaemia/lymphoma
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12626000036314
Curative
Phase 3
Not yet recruiting
To determine whether hypofractionated radiotherapy (HF-RT) combined with concurrent and adjuvant temozolomide (TMZ) provides survival outcomes that are not inferior to those of conventional fractionated radiotherapy (CF-RT) with concurrent and adjuvant TMZ in adults with newly diagnosed Grade 4 Glioblastoma (
CONCISE
)
alkylating agent
radiotherapy
Central nervous system cancer
Glioblastoma
ACTRN12625001031459
Haem
Phase 2
Not yet recruiting
Place-of-care manufactured anti-BCMA chimeric antigen receptor (CAR) T-cells (ARI0002h) in patients with relapsed/refractory multiple myeloma.
autologous CAR-T-cell therapy,BCMA-targeting
+ alkylating agent
Multiple myeloma
WA
6000 - Perth - Royal Perth Hospital
ACTRN12625001003460
Haem
Phase 3
Not yet recruiting
ALLG AMLM29
CAVIAT-R
(Combining Anti-BCL2 and intensive chemotherapy in Acute Myeloid Leukaemia (AML) Trial- Randomised) : a multicentre phase III trial for newly diagnosed AML
Amsacrine
Bcl2 inhibitor
Cytarabine
Filgrastim
Fludarabine
Idarubicin
Pegfilgrastim
Posaconazole
Venetoclax
alkylating agent
anthracycline
antimetabolite
azole antifungal
cancer therapy
cancer therapy,Bcl2-targeting
cytotoxic chemotherapy
+ alkylating agent
Acute myeloid leukaemia
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12625000965404
Haem
Phase 3
Not yet recruiting
ALLG CLL10/CLLRT2: A prospective, open-label, randomised, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation (
CLL-RT2
)
BTK inhibitor
bispecific T-cell engager,CD20-targeting
+ alkylating agent
Cancer
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma,Richter's transformation
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12624001142527
Haem
Phase 4
Not yet recruiting
Safety analysis of 90-minute Obinutuzumab infusion in Chronic Lymphocytic Leukaemia (CLL) and Follicular Lymphoma (FL) patients (
nil
)
anti-CD20 monoclonal antibody
+ alkylating agent
Chronic lymphocytic leukaemia
Follicular lymphoma
QLD
4870 - Cairns - Cairns Base Hospital
ACTRN12624000110583
Advanced
Not Applicable
Recruiting
SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies (
SOCRATES-PILOT
)
AR-targeted agent,next generation
AR-targeted agent,second generation
Abiraterone
Anastrozole
Apalutamide
Atorvastatin
Bevacizumab
CYP17A1 inhibitor
Darolutamide
Enzalutamide
HMG-CoA reductase inhibitor
Letrozole
Lomustine
Nab-paclitaxel
Niraparib
Olaparib
PARP1/2 inhibitor
PARP1 inhibitor
PARP2 inhibitor
PARP inhibitor
Paclitaxel
alkylating agent
anti-VEGF monoclonal antibody
antiandrogen
antiandrogen,nonsteroidal
antiandrogen,nonsteroidal,second generation
aromatase inhibitor
cancer therapy
cancer therapy,AR-targeting
cancer therapy,CYP17A1-targeting
cancer therapy,HMG-CoA reductase-targeting
cancer therapy,PARP-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,androgen axis-targeting
endocrine therapy,oestrogen axis-targeting
immuno-oncology therapy,VEGF-targeting
oestrogen receptor-targeting therapy
taxane
+ alkylating agent
Cervical cancer
Glioblastoma
Ovarian cancer
Prostate cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
ACTRN12623001301651
Curative
Not Applicable
Recruiting
GeneScreen 5-FU: DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Solid Organ Cancer Patients (
GeneScreen-5-FU
)
fluoropyrimidine
+ alkylating agent
Cancer
ACTRN12622001366741
Haem
Phase 2
Recruiting
Investigating the efficacy of Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The
RIDDLE-M-X
trial
XPO1 inhibitor
+ alkylating agent
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2640 - Albury - Border Medical Oncology Research Unit
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12622001232729
Haem
Phase 2
Recruiting
A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation (
The-ANZHIT-2-study
)
Cyclophosphamide
Fludarabine
Mesna
Radiotherapy
Tacrolimus
Treosulfan
alkylating agent
antimetabolite
calcineurin inhibitor
cancer therapy
cytotoxic chemotherapy
sodium mercaptoethanesulfonate
+ alkylating agent
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Chronic myelogenous leukaemia
Myelodysplastic syndrome
Myeloproliferative Neoplasm
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12622000308796
Haem
Phase 1
Recruiting
A phase 1 study to assess the safety of short-course treatment with venetoclax prior to non-myeloablative stem cell transplantation for patients with haematological malignancies. (
VICTORY-study
)
Bcl2 inhibitor
+ alkylating agent
Chronic lymphocytic leukaemia
Leukaemia
Lymphoma
Multiple myeloma
Myelodysplastic syndrome
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
ACTRN12621000802808
Advanced
Phase 2
Recruiting
A pilot open label study of [177Lu]Lu-octretotate and temozolomide in the treatment of succinate dehydrogenase-associated locally advanced or metastatic pheochromocytoma and paraganglioma in adults. (
LU-TEMP
)
alkylating agent
Paraganglioma
Phaeochromocytoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
ACTRN12619000079145
Haem
Phase 1
Not yet recruiting
A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (
The-AutoCAR19-Trial
)
autologous CAR-T-cell therapy,CD19-targeting
+ alkylating agent
Acute lymphoblastic leukaemia
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6000 - Perth - Royal Perth Hospital
ACTRN12613001154796
Curative
Phase 2
Not yet recruiting
A phase 2 trial of cyclophosphamide as prophylaxis for graft-versus-host disease after HLA-identical allogeneic donor transplantation using reduced intensity conditioning therapy (
PT-CYCLO
)
alkylating agent
Haematological malignancy
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
ACTRN12609000504213
Curative
Not Applicable
Recruiting
Cardiac monitoring with echocardiogram and tissue doppler imaging (TDI) and serum biomarkers to assess for cardiotoxicity with anthracyclines in women during adjuvant chemotherapy for breast cancer. (
ECHO
)
Cyclophosphamide
Docetaxel
Fluorouracil
alkylating agent
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
taxane
+ alkylating agent
Breast cancer
ACTRN12609000260224
Advanced
Phase 1
Recruiting
In patients with malignant mesothelioma (MM) and non-small cell lung cancer (NSCLC) does low-dose iterative cyclophosphamide in combination with conventionally dosed pemetrexed-based chemotherapy decrease regulatory T cell numbers and increase antigen-specific and non-specific cellular immunity. (
No
)
alkylating agent
antimetabolite
Mesothelioma
Non-small cell lung cancer
ACTRN12608000129381
Haem
Phase 2
Recruiting
Cotransplantation of mesenchymal stem cells with nonmyeloablative haploidentical peripheral blood stem cells without T cells deleted for high-risk acute leukemia: to reduce the severity of graft versus host disease and relapse
Cyclophosphamide
Cytarabine
Fludarabine
alkylating agent
antimetabolite
cancer therapy
cytotoxic chemotherapy
+ alkylating agent
Leukaemia
ACTRN12608000013369
Advanced
Phase 2
Not yet recruiting
Immune regulation and timing of chemotherapy in advanced/recurrent ovarian cancer to evaluate tumour response
Cyclophosphamide
alkylating agent
cancer therapy
cytotoxic chemotherapy
+ alkylating agent
Ovarian cancer
ACTRN12606000433505
Haem
Phase 1 / Phase 2
Not yet recruiting
A Three-Stage Phase I/II Dose-Escalation Study of High-Dose Melphalan with Palifermin for Patients with Multiple Myeloma to Determine a New Maximum Tolerated Dose (MTD) of Melphalan for use in Autografting (
ALLG
)
alkylating agent
keratinocyte growth factor
Multiple myeloma
ACTRN12606000030572
Curative
Phase 2
Recruiting
An open label phase 2 study of doxorubicin and cyclophosphamide followed by paclitaxel (AC-T) delivered every 14 days with pegfilgrastim and darbepoetin alfa support for the adjuvant treatment of women with breast cancer (
ACCELERATE
)
alkylating agent
anthracycline
erythropoiesis stimulating agent
granulocyte colony stimulating factor
taxane
Breast cancer
ACTRN12605000731695
Advanced
Phase 2
Not yet recruiting
Phase II study of the addition of darbepoetin alfa (Aranesp) and pegfilgrastim (Neulasta) support for optimal dose-dense chemotherapy for early breast cancer
erythropoiesis stimulating agent
granulocyte colony stimulating factor
+ alkylating agent
Breast cancer
ACTRN12605000377639
Advanced
Recruiting
A randomised phase II study comparing the safety and efficacy of capecitabine with capecitabine and oral cyclophosphamide in patients with advanced breast cancer (
Cyclox-II
)
alkylating agent
fluoropyrimidine
Breast cancer
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (55)
Not yet recruiting (12)
Recruitment Country and State
VIC (41)
NSW (40)
WA (33)
QLD (33)
NZ (18)
SA (15)
TAS (4)
ACT (1)
Phase
Phase 1 (5)
Phase 1 / Phase 2 (9)
Phase 2 (22)
Phase 2 / Phase 3 (3)
Phase 3 (23)
Phase 4 (1)
Trial Type
Haem (28)
Advanced (14)
Paed (12)
Curative (8)
Radonc (5)
Paed (1)
Cancer Therapy Class
CD20
19%
CD19
16%
KIT
7%
cereblon
6%
proteasome
6%
VEGFR2
6%
PD-1
6%
PD-1/PD-L1
6%
RET
6%
VEGFR
6%
Bcl2
6%
AXL
4%
HIF2a
4%
MET
4%
ROS1
4%
VEGF
4%
PARP
4%
Trop2
4%
BTK
4%
PI3K delta
4%
mTOR
4%
mTORC1
4%
CD38
3%
MER
3%
GD2
3%
BCMA
3%
LAG3
3%
ROR1
3%
PI3K
3%
PI3Kalpha
3%
mTORC2
3%
CDK4
3%
CDK6
3%
FGFR
3%
FGFR1
3%
FGFR1/2/3
3%
FGFR2
3%
FGFR3
3%
FGFR4
3%
PDGFR
3%
IL-2
1%
GPRC5D
1%
ALK
1%
DPD
1%
orotate phosphoribosyltransferase
1%
B7H3
1%
IDH1
1%
IDH1 R132
1%
BCR-ABL1
1%
PDGFRA
1%
SRC
1%
YES1
1%
IL-6
1%
ERBB2
1%
PARP1-selective
1%
CD79b
1%
ATM
1%
CD22
1%
AR
1%
CYP17A1
1%
HMG-CoA reductase
1%
androgen axis
1%
oestrogen axis
1%
XPO1
1%
Facility
6009 - Perth - Perth Children's Hospital (14)
2050 - Camperdown - Chris O'Brien Lifehouse (12)
3000 - Melbourne - Peter MacCallum Cancer Centre (12)
4101 - South Brisbane - Queensland Children's Hospital (12)
2031 - Randwick - Sydney Children's Hospital (10)
4102 - Woolloongabba - Princess Alexandra Hospital (9)
NZ.1023 - Grafton - Starship Children's Hospital (9)
2145 - Westmead - The Children's Hospital at Westmead (9)
3004 - Melbourne, Southbank - Alfred Health (8)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (8)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (8)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (8)
6000 - Perth - Royal Perth Hospital (7)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (7)
3065 - Fitzroy - St Vincent's Hospital Melbourne (6)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (6)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (6)
2305 - New Lambton Heights - John Hunter Children's Hospital (6)
3052 - Parkville - Royal Children's Hospital Melbourne (6)
2139 - Concord - Concord Repatriation General Hospital (5)
2170 - Liverpool - Liverpool Hospital (5)
6150 - Murdoch - Fiona Stanley Hospital (5)
3168 - Clayton - Monash Medical Centre (5)
2031 - Randwick - Prince of Wales Hospital (5)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (5)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (5)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
3002 - East Melbourne - Epworth Freemasons (4)
7000 - Hobart - Royal Hobart Hospital (4)
2109 - North Ryde - Macquarie University Hospital (3)
5042 - Bedford Park - Flinders Medical Centre (3)
3066 - Epping - Northern Hospital (3)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (3)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (3)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
4215 - Southport - Gold Coast University Hospital (2)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
4812 - Townsville - Townsville University Hospital (2)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
3168 - Clayton - Monash Children's Hospital (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
2217 - Kogarah - St George Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
NZ.6035 - Wellington - Bowen Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
4350 - Toowoomba - Toowoomba Hospital (1)
6005 - West Perth - Perth Blood Institute (1)
2500 - Wollongong - Cancer Care Wollongong (1)
5000 - Adelaide - Cancer Research SA (1)
6009 - Nedlands - Hollywood Private Hospital (1)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2605 - Garran - The Canberra Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4870 - Cairns - Cairns Base Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
Cancer Type
Cancer
Haematological malignancy
Solid tumour
Lymphoma
Non-Hodgkin's lymphoma
B-cell malignancy
Mature B-cell malignancy
B-cell lymphoma
Neurological cancer
Leukaemia
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Central nervous system cancer
Lymphoid leukaemia
Plasma cell disorder
Multiple myeloma
Glioma
High-grade glioma
Malignant glioma
Glioblastoma
Chronic lymphocytic leukaemia
Sarcoma
Breast cancer
Acute lymphoblastic leukaemia
Urogenital cancer
Small lymphocytic lymphoma
Lung cancer
Respiratory tract cancer
Thoracic cancer
Diffuse intrinsic pontine glioma
H3K27M-mutant glioma
Soft tissue sarcoma
Clear cell renal cell carcinoma
Kidney cancer
Neuroblastic tumour
Neuroblastoma
Peripheral nervous system tumour
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Wilms tumour
Anaplastic astrocytoma
Rhabdomyosarcoma
Male genital cancers
B-cell acute lymphoblastic leukaemia/lymphoma
Acute myeloid leukaemia
Myeloid leukaemia
Gynaecological cancer
Ovarian cancer
Myelodysplastic syndrome
Myeloproliferative neoplasm
Melanoma
Skin cancer
AL amyloidosis
Amyloidosis
Breast adenocarcinoma
HER2-negative breast cancer
Triple-negative breast cancer
Mantle cell lymphoma
Diffuse midline glioma
Astrocytoma
Low-grade glioma
Oligodendroglioma
Diffuse hemispheric glioma
Retinoblastoma
Alveolar rhabdomyosarcoma
Embryonal rhabdomyosarcoma
Sclerosing rhabdomyosarcoma
Choriocarcinoma
Germ cell tumour
Germinoma
Mixed germ cell tumour
Non-seminoma
Teratoma
Testicular cancer
Testicular embryonal carcinoma
Yolk sac tumour
Leiomyosarcoma
Liposarcoma
Peritoneal cancer
Mixed phenotype acute leukaemia
Diffuse large B-cell lymphoma,Richter's transformation
Follicular lymphoma
Cervical cancer
HPV-related cancer
HPV16-positive cancer
Prostate cancer
Viral-related cancer
Chronic leukaemia
Chronic myelogenous leukaemia
Adrenal cancer
Endocrine gland cancer
Neuroendocrine tumour
Paraganglioma
Phaeochromocytoma
Mesothelioma
Non-small cell lung cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy